What We're Reading: Page 159
Industry reads hand-picked by our editors
Mar 10, 2021
-
Bloomberg
Biden Duo's Nudge Eased Merck-J&J Logjam to Speed Vaccine Output
-
NPR
In The '24th Mile' Of A Marathon, Fauci And Collins Reflect On Their Pandemic Year
-
The Sunday Times
GlaxoSmithKline doubles cash paid to doctors for promoting its drugs
-
In the Pipeline
Drug Approvals Over the Last Ten Years
Mar 09, 2021
-
The Boston Globe
For Biogen, it’s been a rough ride
-
The New York Times
Pandemic Forces F.D.A. to Sharply Curtail Drug Company Inspections
-
The Atlantic
The Differences Between the Vaccines Matter
Mar 08, 2021
-
The New York TImes
How Emergent BioSolutions Put an ‘Extraordinary Burden’ on the U.S.’s Troubled Stockpile
-
Financial Times
Pharma groups spend billions to tap into booming China healthcare
-
The Wall Street Journal
Russian Disinformation Campaign Aims to Undermine Confidence in Pfizer, Other Covid-19 Vaccines, U.S. Officials Say
-
STAT
How IBM's audacious plan to 'change the face of health care' fell apart
Mar 05, 2021
Mar 04, 2021
-
STAT
Kronos Bio speeds development of genetically targeted leukemia drug
-
The Wall Street Journal
Mount Sinai Leases Space for Biotech Campus on Manhattan’s West Side
-
In the Pipeline
How to Administer RNA – And How to Do It Again
-
The New York Times
India's Covaxin Covid-19 Vaccine, Already in Use, Shows Promise in Trials
Mar 03, 2021
Mar 02, 2021
-
Chemical & Engineering News
The fight against fungi
-
The Wall Street Journal
Covid-19 Vaccines Yield Breakthroughs in Long-Term Fight Against Infectious Disease
-
Evaluate Vantage
Early Morphic data hint at a threat to Entyvio
-
Science
New immunotherapy drugs target two evasive cancer-driving proteins
Previous
